These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 34381413)

  • 1. RNF213 and GUCY1A3 in Moyamoya Disease: Key Regulators of Metabolism, Inflammation, and Vascular Stability.
    Mineharu Y; Miyamoto S
    Front Neurol; 2021; 12():687088. PubMed ID: 34381413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNF213 as the major susceptibility gene for Chinese patients with moyamoya disease and its clinical relevance.
    Zhang Q; Liu Y; Zhang D; Wang R; Zhang Y; Wang S; Yu L; Lu C; Liu F; Zhou J; Zhang X; Zhao J
    J Neurosurg; 2017 Apr; 126(4):1106-1113. PubMed ID: 27128593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caveolin-1, Ring finger protein 213, and endothelial function in Moyamoya disease.
    Bang OY; Chung JW; Kim SJ; Oh MJ; Kim SY; Cho YH; Cha J; Yeon JY; Kim KH; Kim GM; Chung CS; Lee KH; Ki CS; Jeon P; Kim JS; Hong SC; Moon GJ
    Int J Stroke; 2016 Dec; 11(9):999-1008. PubMed ID: 27462098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNF213 loss-of-function promotes pathological angiogenesis in moyamoya disease via the Hippo pathway.
    Ye F; Niu X; Liang F; Dai Y; Liang J; Li J; Wu X; Zheng H; Qi T; Sheng W
    Brain; 2023 Nov; 146(11):4674-4689. PubMed ID: 37399508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moyamoya disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct ubiquitin-transfer mechanism.
    Ahel J; Lehner A; Vogel A; Schleiffer A; Meinhart A; Haselbach D; Clausen T
    Elife; 2020 Jun; 9():. PubMed ID: 32573437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and Functional Characterization of RNF213 (Mysterin) R4810K, a Susceptibility Mutation of Moyamoya Disease, in Angiogenesis In Vitro and In Vivo.
    Kobayashi H; Matsuda Y; Hitomi T; Okuda H; Shioi H; Matsuda T; Imai H; Sone M; Taura D; Harada KH; Habu T; Takagi Y; Miyamoto S; Koizumi A
    J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26126547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biallelic variants in NOS3 and GUCY1A3, the two major genes of the nitric oxide pathway, cause moyamoya cerebral angiopathy.
    Guey S; Hervé D; Kossorotoff M; Ha G; Aloui C; Bergametti F; Arnould M; Guenou H; Hadjadj J; Dubois Teklali F; Riant F; Balligand JL; Uzan G; Villoutreix BO; Tournier-Lasserve E
    Hum Genomics; 2023 Mar; 17(1):24. PubMed ID: 36941667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disrupted nitric oxide signaling due to GUCY1A3 mutations increases risk for moyamoya disease, achalasia and hypertension.
    Wallace S; Guo DC; Regalado E; Mellor-Crummey L; Bamshad M; Nickerson DA; Dauser R; Hanchard N; Marom R; Martin E; Berka V; Sharina I; Ganesan V; Saunders D; Morris SA; Milewicz DM
    Clin Genet; 2016 Oct; 90(4):351-60. PubMed ID: 26777256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of mitochondrial ClpP, Lonp1, and Tfam triggers transcriptional induction of Rnf213, a susceptibility factor for moyamoya disease.
    Key J; Maletzko A; Kohli A; Gispert S; Torres-Odio S; Wittig I; Heidler J; Bárcena C; López-Otín C; Lei Y; West AP; Münch C; Auburger G
    Neurogenetics; 2020 Jul; 21(3):187-203. PubMed ID: 32342250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of α1β1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia.
    Hervé D; Philippi A; Belbouab R; Zerah M; Chabrier S; Collardeau-Frachon S; Bergametti F; Essongue A; Berrou E; Krivosic V; Sainte-Rose C; Houdart E; Adam F; Billiemaz K; Lebret M; Roman S; Passemard S; Boulday G; Delaforge A; Guey S; Dray X; Chabriat H; Brouckaert P; Bryckaert M; Tournier-Lasserve E
    Am J Hum Genet; 2014 Mar; 94(3):385-94. PubMed ID: 24581742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNF213 Rare Variants in Slovakian and Czech Moyamoya Disease Patients.
    Kobayashi H; Brozman M; Kyselová K; Viszlayová D; Morimoto T; Roubec M; Školoudík D; Petrovičová A; Juskanič D; Strauss J; Halaj M; Kurray P; Hranai M; Harada KH; Inoue S; Yoshida Y; Habu T; Herzig R; Youssefian S; Koizumi A
    PLoS One; 2016; 11(10):e0164759. PubMed ID: 27736983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic analysis of
    Tashiro R; Fujimura M; Sakata H; Endo H; Tomata Y; Sato-Maeda M; Niizuma K; Tominaga T
    Neurol Res; 2019 Sep; 41(9):811-816. PubMed ID: 31064275
    [No Abstract]   [Full Text] [Related]  

  • 13. Rare variants in RNF213, a susceptibility gene for moyamoya disease, are found in patients with pulmonary hypertension and aggravate hypoxia-induced pulmonary hypertension in mice.
    Kobayashi H; Kabata R; Kinoshita H; Morimoto T; Ono K; Takeda M; Choi J; Okuda H; Liu W; Harada KH; Kimura T; Youssefian S; Koizumi A
    Pulm Circ; 2018; 8(3):2045894018778155. PubMed ID: 29718794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic analysis of RNF213 p.R4810K variant in non-moyamoya intracranial artery stenosis/occlusion disease in a Chinese population.
    Zhang T; Guo C; Liao X; Xia J; Wang X; Deng J; Yan J
    Environ Health Prev Med; 2017 Apr; 22(1):41. PubMed ID: 29165136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics and Biomarkers of Moyamoya Disease: Significance of RNF213 as a Susceptibility Gene.
    Fujimura M; Sonobe S; Nishijima Y; Niizuma K; Sakata H; Kure S; Tominaga T
    J Stroke; 2014 May; 16(2):65-72. PubMed ID: 24949311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemorrhagic Onset Intracranial Artery Dissection of Middle Cerebral Artery Followed by Progressive Arterial Stenosis with Genetic Variant RNF213 p.Arg4810Lys (rs112735431).
    Shinya Y; Miyawaki S; Nakatomi H; Shin M; Teraoka A; Saito N
    World Neurosurg; 2020 Sep; 141():192-195. PubMed ID: 32438004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early onset of moyamoya syndrome in a Down syndrome patient with the genetic variant RNF213 p.R4810K.
    Chong PF; Ogata R; Kobayashi H; Koizumi A; Kira R
    Brain Dev; 2015 Sep; 37(8):822-4. PubMed ID: 25547042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into TNFα/PTP1B and PPARγ pathway through RNF213- a link between inflammation, obesity, insulin resistance, and Moyamoya disease.
    Sarkar P; Thirumurugan K
    Gene; 2021 Mar; 771():145340. PubMed ID: 33333224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of RNF213 polymorphism on clinical features and long-term outcome in moyamoya disease.
    Kim EH; Yum MS; Ra YS; Park JB; Ahn JS; Kim GH; Goo HW; Ko TS; Yoo HW
    J Neurosurg; 2016 May; 124(5):1221-7. PubMed ID: 26430847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moyamoya Vasculopathy in Neurofibromatosis Type 1 Pediatric Patients: The Role of Rare Variants of
    Ognibene M; Scala M; Iacomino M; Schiavetti I; Madia F; Traverso M; Guerrisi S; Di Duca M; Caroli F; Baldassari S; Tappino B; Romano F; Uva P; Vozzi D; Chelleri C; Piatelli G; Diana MC; Zara F; Capra V; Pavanello M; De Marco P
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.